Maxcyte (MXCT) Equity Ratio (2020 - 2026)

Maxcyte (MXCT) has 7 years of Equity Ratio data on file, last reported at 0.86 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.86, changed 0.45% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.86 (changed 0.45% YoY), and the FY2025 annual result was 0.85, down 1.68% from the prior year.
• Equity Ratio climbed to 0.86 in Q1 2026 per MXCT's latest filing, from 0.85 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.9 in Q1 2022 and troughed at 0.84 in Q3 2025.
• A 5-year average of 0.87 and a median of 0.87 in 2023 frame the typical range for Equity Ratio.
• On a YoY basis, Equity Ratio climbed as much as 4.9% in 2022 and fell as far as 6.6% in 2022.
• A 5-year view of Equity Ratio shows it stood at 0.89 in 2022, then decreased by 2.32% to 0.87 in 2023, then slipped by 0.48% to 0.86 in 2024, then slipped by 1.68% to 0.85 in 2025, then climbed by 1.94% to 0.86 in 2026.
• Business Quant data shows MXCT's Equity Ratio at 0.86 in Q1 2026, 0.85 in Q4 2025, and 0.84 in Q3 2025.